Home › Funds › Catalio Capital Management, LP › MLYS
Catalio Capital Management, LP position in MLYS
Mineralys Therapeutics, Inc. · Health Care
Catalio Capital Management, LP reported holding 648,722 shares of MLYS (Mineralys Therapeutics, Inc.) in its Q2 2026 13F filing — a position valued at US$17.5M, representing 3.29% of its reported portfolio and ranking #12 among its reported holdings. Catalio Capital Management, LP has disclosed MLYS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's MLYS position evolved
Catalio Capital Management, LP first disclosed a stake in MLYS in Q4 2025 at 331,849 shares (US$12.0M). The position peaked in Q2 2026 at 648,722 shares, worth US$17.5M. Across 3 filings, Catalio Capital Management, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 648,722 shares valued at US$17.5M — an increase of 209,681 shares quarter over quarter.. Notable position changes include a 32% increase in Q1 2026 (shares were roughly flat over the following quarter), a 48% increase in Q2 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 331.85K | $12.04M | New |
| Q1 2026 | 439.04K | $11.89M | Add |
| Q2 2026 | 648.72K | $17.50M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (Mineralys Therapeutics, Inc.) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held MLYS?
Catalio Capital Management, LP has disclosed MLYS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Catalio Capital Management, LP's current position in MLYS?
As of Q2 2026, Catalio Capital Management, LP holds 648.72K shares of MLYS (Mineralys Therapeutics, Inc.), valued at $17.50M, representing 3.29% of its reported portfolio and ranking #12.
Has Catalio Capital Management, LP been buying or selling MLYS?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in MLYS. The position peaked in Q2 2026 at 648.72K shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.